Surface Oncology, Inc (SURF)

Etorro trading 970x250
Surface Oncology, Inc (SURF) Logo

About Surface Oncology, Inc

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: 50 Hampshire Street, Cambridge, MA, United States, 02139

Surface Oncology, Inc News and around…

Latest news about Surface Oncology, Inc (SURF) common stock and company :

Should Weakness in Surface Oncology, Inc.'s (NASDAQ:SURF) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
26 Nov, 2021 Yahoo! Finance

It is hard to get excited after looking at Surface Oncology's (NASDAQ:SURF) recent performance, when its stock has...

How The Pieces Add Up: OMFS Targets $52
18 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $51.52 per unit.

RSI Alert: Surface Oncology (SURF) Now Oversold
11 Nov, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

This Company Says It's One Step Closer to Transforming Cancer Treatment with its Latest Groundbreaking Immunotherapy
11 Nov, 2021 FinancialContent

Photo by Martha Dominguez de Gouveia on Unsplash The following post was written and/or published as a collaboration between ...

Preclinical Data Supporting Therapeutic Potential of Surface Oncology’s Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting
09 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that two scientific posters sharing updated preclinical data from Surface Oncology’s two lead clinical-stage antibody therapies, SRF617 (targeting CD39) and SRF388 (targeting IL-27), will be presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting, to

10 Best Stocks Under $11 in Cathie Wood’s Portfolio
08 Nov, 2021 Yahoo! Finance

In this article, we discuss the 10 best stocks under $11 in Cathie Wood’s portfolio based on Q2 holdings of the fund. If you want to skip our detailed analysis of Wood’s history, investment philosophy, and hedge fund performance, go directly to the 5 Best Stocks Under $11 in Cathie Wood’s Portfolio. Catherine Duddy Wood […]

Surface Oncology to Participate in the 2021 Annual Cowen IO Next Summit
08 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the upcoming Cowen Fifth Annual IO Next Summit on Monday, November 15, 2021 at 12:45 p.m. ET. The live audio and subsequent archived webcast of the fireside chat will be accessible from the

Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021
04 Nov, 2021 Yahoo! Finance

Company to initiate randomized Phase 2 clinical study evaluating SRF388 in combination with Roche’s atezolizumab and bevacizumab, in patients with treatment-naïve HCCCAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results for the third quarter 2021, and provided a corporate update on recent highlights and anticip

Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting
02 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that scientific posters sharing preclinical data will be presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting, to be held virtually and at the Walter E. Washington Convention Center in Washington, D.C. November 10-14, 2021. The posters include prec

How To Lower Risk On Your Biotech Plays
24 Oct, 2021 FinancialContent

You can hit some big home runs in the biotech sector, but you need to manage your risk when trading these stocks. If you handle your risk properly, you’ll be able to take more big swings.

Bullish Two Hundred Day Moving Average Cross - SURF
12 Oct, 2021 FinancialContent

In trading on Tuesday, shares of Surface Oncology Inc (SURF) crossed above their 200 day moving average of $8.03, changing hands as high as $8.32 per share. Surface Oncology Inc shares are currently trading up about 1.9% on the day..

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?
12 Oct, 2021 Yahoo! Finance

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

We Did The Math OMFS Can Go To $49
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.97 per unit.

Hedge Funds Aren’t Crazy About Surface Oncology, Inc. (SURF) Anymore
04 Oct, 2021 Yahoo! Finance

The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

Surface Oncology Announces New Randomized Phase 2 Clinical Study Evaluating SRF388 in Patients with First-Line Hepatocellular Carcinoma in Clinical Collaboration with Roche
04 Oct, 2021 Yahoo! Finance

Study initiation underway with first patient dosed by early 2022CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced details about its plan to initiate a randomized Phase 2 clinical study evaluating SRF388, a potential first-in-class antibody against IL-27, in combination with Roche’s atezolizumab and bevacizumab, in patients

Why AstraZeneca and Surface Oncology Rose Today
20 Sep, 2021 FinancialContent

The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi.

35 Stocks Moving In Monday's Mid-Day Session
20 Sep, 2021 FinancialContent

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. ...

Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
20 Sep, 2021 FinancialContent
48 Biggest Movers From Friday
20 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
17 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 53.98% to $3.48 during Friday's pre-market ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
17 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips There's only one day of trading left so let's start it off right with a look at the biggest pre-market stock movers for Friday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

15 Stocks Moving in Friday's Pre-Market Session
17 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ...

New Strong Sell Stocks for September 13th
13 Sep, 2021 Yahoo! Finance

AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.

How Bad Are Surface Oncology's Earnings? | Return On Capital Employed
08 Sep, 2021 FinancialContent

Surface Oncology (NASDAQ:SURF) brought in sales totaling $515.00 thousand during Q2 according to data provided by Benzinga Pro.However, ...

Russell 2000 Headed 23% Higher, If Analysts Got The Components Right
27 Aug, 2021 FinancialContent

The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation metrics, others apply a broad macro view of the economy..

What Is The Ownership Structure Like For Surface Oncology, Inc. (NASDAQ:SURF)?
23 Aug, 2021 Yahoo! Finance

The big shareholder groups in Surface Oncology, Inc. ( NASDAQ:SURF ) have power over the company. Institutions often...

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021
05 Aug, 2021 FinancialContent
Relative Strength Alert For Surface Oncology
04 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

First Week of September 17th Options Trading For Surface Oncology
16 Jul, 2021 FinancialContent

Investors in Surface Oncology Inc (SURF) saw new options begin trading this week, for the September 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SURF options chain for the new September 17th contracts and identified one put and one call contract of particular interest.

Surface Oncology, Inc (SURF) is a NASDAQ Common Stock listed in , ,

970x250